Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris

Cutis

Volumn 78, Issue 4 SUPPL., 2006, Pages 11-20

  Stewart, Daniel M ^a   Torok, Helen Mary ^b   Weiss, Jonathan S ^c   Plott, R Todd ^d  

^a Midwest Cutaneous Research Corp   (United States)

^b Trillium Creek Dermatology Center   (United States)

^c Gwinnett Clinical Research Center   (United States)

^d Medicis Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MINOCYCLINE;

ACNE VULGARIS; ADOLESCENT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MINOCYCLINE; TREATMENT OUTCOME;

EID: 33750860795     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449-453.
2. Sainte-Marie I, Tenaud I, Jumbou O, et al. Minocycline modulation of alpha-MSH production by keratinocytes in vitro. Acta Derm Venereol. 1999;79:265-267.
3. Celerier P, Litoux P, Dreno B. In vitro modulation of epidermal inflammatory cytokines (IL-1-alpha, IL-6, TNF alpha) by minocycline. Arch Dermatol Res. 1996;288:411-414.
4. Katsambas AD. Why and when the treatment of acne fails. what to do. Dermatology. 1998;196:158-161.
5. Bernier C, Dreno B. Minocycline. Ann Dermatol Venereol. 2001;128:627-637.
6. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355-366.
7. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993;128:556-560.
8. Plott RT, Wortzman MS. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis. 2006;78(suppl 4):6-10.
9. Data on file. Scottsdale, Ariz: Medicis Pharmaceutical Corporation; 2003.